In January, over 60 world-renowned experts in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit. This industry-focused event aims to advance effectiveness, durability, and minimally invasive techniques in retinal drug delivery.
The 3-day summit will cover a wide range of cutting-edge topics, including:
• Suprachoroidal drug delivery
• Gene therapy transduction
• Sustained-release formulations.
• Release kinetics
Attendees will have the chance to explore innovative strategies and clinical applications of these emerging technologies in the field of retinal and ocular care.
Experts from leading organizations such as Genentech, AbbVie, Bayer, Clearside Biomedical, Ocular Therapeutix, Regenxbio, Regeneron, and Eyepoint Pharmaceuticals will present at the event. These sessions will provide opportunities for sharing new insights, discussing recent findings, and exploring the latest advancements in ophthalmic drug delivery.
The summit will kick off with a pre-conference workshop featuring presentations by Everads Therapy and Aviceda. This workshop will focus on suprachoroidal delivery in gene therapy, addressing the unique challenges in the design of ophthalmic clinical trials.
During the main conference days, key data readouts from companies such as Genentech, Alcon, GelMEDIX, and Ray Therapeutics will be shared. These updates will offer attendees valuable insights into the latest developments and progress within the industry.
In addition to the scientific presentations, the summit is structured to foster meaningful networking opportunities. Attendees will be able to connect with peers, exchange ideas, and collaborate on future advancements in ophthalmic drug delivery technologies.
For more information and registration visit the event’s website.